69 related articles for article (PubMed ID: 38689269)
1. [Efficacy and prognostic factors of allogeneic hematopoietic stem cell transplantation in the treatment of secondary acute myeloid leukemia].
Yuan XL; Wu YB; Song XL; Chen Y; Lu Y; Lai XY; Shi JM; Liu LZ; Zhao YM; Yu J; Yang LX; Lan JP; Cai Z; Huang H; Luo Y
Zhonghua Xue Ye Xue Za Zhi; 2024 Jan; 45(1):41-47. PubMed ID: 38527837
[No Abstract] [Full Text] [Related]
2. Multi-target measurable residual disease assessed by error-corrected sequencing in patients with acute myeloid leukemia: An ALFA study.
Hirsch P; Lambert J; Bucci M; Deswarte C; Boudry A; Lambert J; Fenwarth L; Micol JB; Terré C; Celli-Lebras K; Thomas X; Dombret H; Duployez N; Preudhomme C; Itzykson R; Delhommeau F
Blood Cancer J; 2024 Jun; 14(1):97. PubMed ID: 38871702
[TBL] [Abstract][Full Text] [Related]
3. Droplet digital PCR: An effective method for monitoring and prognostic evaluation of minimal residual disease in JMML.
Mao S; Lin Y; Qin X; Miao Y; Luo C; Luo C; Wang J; Huang X; Zhu H; Lai J; Chen J
Br J Haematol; 2024 Jun; 204(6):2332-2341. PubMed ID: 38622924
[TBL] [Abstract][Full Text] [Related]
4. Multi-gene measurable residual disease assessed by digital polymerase chain reaction has clinical and biological utility in acute myeloid leukemia patients receiving venetoclax/azacitidine.
Winters AC; Minhajuddin M; Stevens BM; Major A; Bosma G; Abbott D; Miltgen N; Yuan J; Treece AL; Siegele BJ; Ewalt MD; Gutman JA; Jordan CT; Pollyea DA
Haematologica; 2024 Jun; 109(6):1766-1778. PubMed ID: 38105738
[TBL] [Abstract][Full Text] [Related]
5. IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients.
Pulsipher MA; Carlson C; Langholz B; Wall DA; Schultz KR; Bunin N; Kirsch I; Gastier-Foster JM; Borowitz M; Desmarais C; Williamson D; Kalos M; Grupp SA
Blood; 2015 May; 125(22):3501-8. PubMed ID: 25862561
[TBL] [Abstract][Full Text] [Related]
6. Mitoxantrone Versus Liposomal Daunorubicin in Induction of Pediatric AML With Risk Stratification Based on Flow Cytometry Measurement of Residual Disease.
Tierens A; Arad-Cohen N; Cheuk D; De Moerloose B; Fernandez Navarro JM; Hasle H; Jahnukainen K; Juul-Dam KL; Kaspers G; Kovalova Z; Lausen B; Norén-Nyström U; Palle J; Pasauliene R; Jan Pronk C; Saks K; Zeller B; Abrahamsson J
J Clin Oncol; 2024 Jun; 42(18):2174-2185. PubMed ID: 38603646
[TBL] [Abstract][Full Text] [Related]
7. Combined usage of Wilms' tumor gene quantitative analysis and multiparameter flow cytometry for minimal residual disease monitoring of acute myeloid leukemia patients after allogeneic hematopoietic stem cells transplantation.
Hao Y; Cheng Y; Wu Q; Zhang A; Jiang X; Xu X
Exp Ther Med; 2018 Feb; 15(2):1403-1409. PubMed ID: 29434724
[TBL] [Abstract][Full Text] [Related]
8. WT1-guided pre-emptive therapy after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia.
Arai S; Tachibana T; Izumi A; Takeda T; Tamai Y; Sato S; Hashimoto C; Fujimaki K; Ishii R; Kabasawa N; Hirasawa A; Inoue Y; Tanaka M; Suzuki T; Nakajima H
Int J Hematol; 2024 May; ():. PubMed ID: 38795248
[TBL] [Abstract][Full Text] [Related]
9. Pretransplantation minimal residual disease monitoring by multiparameter flow cytometry predicts outcomes of AML patients receiving allogeneic hematopoietic stem cell transplantation.
Zhang Y; Wang P; Cassady K; Zou Z; Li Y; Deng X; Yang W; Peng X; Zhang X; Feng Y
Transpl Immunol; 2022 Jun; 72():101596. PubMed ID: 35390479
[TBL] [Abstract][Full Text] [Related]
10. Measurable residual disease monitoring by ddPCR in the early posttransplant period complements the traditional MFC method to predict relapse after HSCT in AML/MDS: a multicenter retrospective study.
Chen W; Huang J; Zhao Y; Huang L; Yuan Z; Gu M; Xu X; Shi J; Luo Y; Yu J; Lai X; Liu L; Fu H; Bao C; Huang X; Zheng Z; Huang H; Hu X; Zhao Y
J Transl Med; 2024 Apr; 22(1):410. PubMed ID: 38689269
[TBL] [Abstract][Full Text] [Related]
11. Patient-Specific Measurable Residual Disease Markers Predict Outcome in Patients With Myelodysplastic Syndrome and Related Diseases After Hematopoietic Stem-Cell Transplantation.
Tobiasson M; Pandzic T; Illman J; Nilsson L; Weström S; Ejerblad E; Olesen G; Björklund A; Olsnes Kittang A; Werlenius O; Lorentz F; Rasmussen B; Cammenga J; Weber D; Lindholm C; Wiggh J; Dimitriou M; Moen AE; Yip Lundström L; von Bahr L; Baltzer-Sollander K; Jädersten M; Kytölä S; Walldin G; Ljungman P; Groenbaek K; Mielke S; Jacobsen SEW; Ebeling F; Cavelier L; Smidstrup Friis L; Dybedal I; Hellström-Lindberg E
J Clin Oncol; 2024 Apr; 42(12):1378-1390. PubMed ID: 38232336
[TBL] [Abstract][Full Text] [Related]
12. Monitoring of post-transplant MLL-PTD as minimal residual disease can predict relapse after allogeneic HSCT in patients with acute myeloid leukemia and myelodysplastic syndrome.
Kong J; Gao MG; Qin YZ; Wang Y; Yan CH; Sun YQ; Chang YJ; Xu LP; Zhang XH; Liu KY; Huang XJ; Zhao XS
BMC Cancer; 2022 Jan; 22(1):11. PubMed ID: 34979982
[TBL] [Abstract][Full Text] [Related]
13. [Effect of minimal residual disease monitoring by multiparameter flow cytometry pre-conditioning on prognosis of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation].
Lu Y; Wu T; Wang H; Zhao YL; Cao XY; Liu DY; Zhang JP; Xiong M; Zhou JR; Sun RJ; Wei ZJ; Ji SQ; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2017 Feb; 38(2):118-123. PubMed ID: 28279035
[No Abstract] [Full Text] [Related]
14. Wilms' tumor gene 1 is an independent prognostic factor for pediatric acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation.
Deng DX; Wen JJ; Cheng YF; Zhang XH; Xu LP; Wang Y; Yan CH; Chen YH; Chen H; Han W; Wang FR; Wang JZ; Qin YZ; Liu KY; Huang XJ; Zhao XS; Mo XD
BMC Cancer; 2021 Mar; 21(1):292. PubMed ID: 33740924
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
